Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

Inclusion Criteria:

Subjects ages 18-65 years old
Diagnosis of moderate-to-severe plaque psoriasis
Plaque affects ≥ 10% of subject's body surface area (BSA)
Subjects prescribed one of the following standard-of-care treatments for their psoriasis: Ustekinumab, Methotrexate, Etanercept, Adalimumab, Narrow Band UVB (311nm), Excimer Laser Treatment (308nm), or Acitretin

Subjects willing to complete a Washout Period prior to Visit 1 (only for subjects currently on a psoriasis treatment):

Discontinue systemic therapies for at least 4 weeks
Discontinue topical therapies for at least 2 weeks
Discontinue phototherapies for at least 2 weeks

Exclusion Criteria:

Subjects who are currently on a psoriasis treatment and unwilling to go through the washout-period
Subjects with a critical illness or who are immunocompromised
Weight is 400lbs or greater
Subjects who are currently pregnant or breastfeeding
Subjects who have metal implants
Subjects who have a pacemaker, stent, or artificial heart valve
History of clinically significant hematological, renal or liver disease

Patients with known co-morbidities that raise biomarkers such as:

History of myocardial infarction (MI)
History of cerebrovascular accident (CVA)
Significant atherosclerosis (defined as the presence of any carotid plaque; or carotid intimal media thickness (cIMT) >75th percentile for age; or the presence of coronary artery calcium score>100)
Poorly controlled diabetes (elevated HbA1c > 8.5)